Fig. 1

Schematic Overview of Study Treatment Regimens and Pharmacodynamic Biomarker Collection: RO6870810 administered at doses of 0.30 mg/kg, 0.45 mg/kg, and 0.65 mg/kg daily for 14 days, and atezolizumab given at 1200 mg intravenously on Day 1 of each 21-day cycle. A. The concomitant regimen involved patients receiving a combination of RO6870810 and atezolizumab from initiation. Tumor biopsies for RNA-sequencing and immunohistochemistry (IHC) were taken at baseline (Cycle 1 Day 1 [C1 D1]) and post-first cycle (Cycle 1 Day 21 [C1 D21]), indicated by purple arrows. Peripheral blood samples for flow cytometry and cytokine profiling, shown by red arrows, were collected on days 1, 8, 15, and 21. This regimen was applied to patients in the dose escalation and both expansion cohorts. B. To evaluate the impact of RO6870810 as a single agent, an alternative group followed a sequential regimen, starting with RO6870810 alone in a run-in cycle before transitioning to combined treatment with atezolizumab. Tumor biopsies were performed at the run-in start (Run-in Day 1 [RI D1]), post-run-in cycle (Run-In Day 21 [RI D21]), and after the initial cycle of combination therapy (C1 D21). Peripheral blood sampling occurred on the same days during the run-in and the first combination treatment cycle, facilitating a comprehensive analysis of treatment-induced changes